Suppr超能文献

CCNA成像工作组关于阿尔茨海默病修饰疗法背景下成像的建议。

Recommendations on Imaging in the Context of Alzheimer's Disease-Modifying Therapies from the CCNA Imaging Workgroup.

作者信息

Duchesne Simon, Collins D Louis, Barlow Laura, Bartha Robert, Black Sandra, Chertkow Howard, Dadar Mahsa, Joshi Manish, Rosa-Neto Pedro, Soucy Jean-Paul, Smith Eric E

机构信息

Department of radiology and nuclear medicine, Université Laval, Québec, QC, Canada.

Quebec Heart and Lung Institute, Québec, QC, Canada.

出版信息

Can J Neurol Sci. 2024 Nov 4:1-9. doi: 10.1017/cjn.2024.338.

Abstract

BACKGROUND

Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) are emerging following successful clinical trials of therapies targeting amyloid beta (Aβ) protofibrils or plaques. Determining patient eligibility and monitoring treatment efficacy and adverse events, such as Aβ-related imaging abnormalities, necessitates imaging with MRI and PET. The Canadian Consortium on Neurodegeneration in Aging (CCNA) Imaging Workgroup aimed to synthesize evidence and provide recommendations on implementing imaging protocols for AD DMTs in Canada.

METHODS

The workgroup employed a Delphi process to develop these recommendations. Experts from radiology, neurology, biomedical engineering, nuclear medicine, MRI and medical physics were recruited. Surveys and meetings were conducted to achieve consensus on key issues, including protocol standardization, scanner strength, monitoring protocols based on risk profiles and optimal protocol lengths. Draft recommendations were refined through multiple iterations and expert discussions.

RESULTS

The recommendations emphasize standardized acquisition imaging protocols across manufacturers and scanner strengths to ensure consistency and reliability of clinical treatment decisions, tailored monitoring protocols based on DMTs' safety and efficacy profiles, consistent monitoring regardless of perceived treatment efficacy and MRI screening on 1.5T or 3T scanners with adapted protocols. An optimal protocol length of 20-30 minutes was deemed feasible; specific sequences are suggested.

CONCLUSION

The guidelines aim to enhance imaging data quality and consistency, facilitating better clinical decision-making and improving patient outcomes. Further research is needed to refine these protocols and address evolving challenges with new DMTs. It is recognized that administrative, financial and logistical capacity to deliver additional MRI and positron emission tomography scans require careful planning.

摘要

背景

在针对淀粉样β(Aβ)原纤维或斑块的治疗方法临床试验取得成功之后,用于阿尔茨海默病(AD)的疾病修饰疗法(DMTs)正在兴起。确定患者的 eligibility 以及监测治疗效果和不良事件,如Aβ相关成像异常,需要进行MRI和PET成像。加拿大衰老神经退行性变协会(CCNA)成像工作组旨在综合证据并就加拿大实施AD DMTs成像方案提供建议。

方法

该工作组采用德尔菲法制定这些建议。招募了来自放射学、神经病学、生物医学工程、核医学、MRI和医学物理学领域的专家。通过调查和会议就关键问题达成共识,包括方案标准化、扫描仪强度、基于风险概况的监测方案以及最佳方案时长。通过多次迭代和专家讨论对建议草案进行完善。

结果

这些建议强调跨制造商和扫描仪强度的标准化采集成像方案,以确保临床治疗决策的一致性和可靠性,根据DMTs的安全性和有效性概况制定量身定制的监测方案,无论治疗效果如何都进行一致的监测,以及在1.5T或3T扫描仪上采用适应性方案进行MRI筛查。最佳方案时长为20 - 30分钟被认为是可行的;并提出了具体序列。

结论

这些指南旨在提高成像数据质量和一致性,促进更好的临床决策并改善患者预后。需要进一步研究以完善这些方案并应对新DMTs带来的不断演变的挑战。认识到提供额外MRI和正电子发射断层扫描的行政、财务和后勤能力需要仔细规划。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验